Avastin Breast Cancer Drug Pulled Off Market; NY Medical Malpractice Attorney Gerry Oginski Explains
Avastin Breast Cancer Drug Pulled Off Market; NY Medical Malpractice Attorney Gerry Oginski Explains – www.Oginski-Law.com Avastin was touted to be the miracle cure for breast cancer patients. It had been proven to choke off the blood supply of the tumor in other types of cancers and had been approved for breast cancer treatment. Avastin happened to be the most popular and best-selling cancer treatment drug for breast cancer. The FDA recently pulled the drug off market because of recent studies that confirmed that the risks far outweighed the benefits. Patients who are on this medication suffered significant side effects and complications. Despite that risk, there are still breast cancer patients who believe that it offers some benefit. Recognizing that possibility, the FDA said that this medication can be prescribed by a doctor “off label.” What that means is that there are significant risks associated with the medication and doctors can still prescribe it for their patients as long as they recognize significant potential for suffering injury. Continuing to take this medication will be an extremely expensive proposition. Your health insurance company will likely no longer pay for this medication that costs almost 0000 per year. According to news reports, Medicare will continue to make payments for the medication, but it is unclear for how long they will continue to do so.Watch the video to learn more. To learn even more about how negligence and medical malpractice cases work in NY, I urge you to explore my educational website http If you have legal questions pick up …
Acadia surges on Parkinson's psychosis drug study
Filed under: drug rehab treatment ny
NEW YORK — Shares of Acadia Pharmaceuticals Inc. more than doubled to their highest price in more than three years Tuesday after the company said its drug pimavanserin reduced psychosis in patients with Parkinson's disease. Acadia said pimavanserin …
Read more on Lexington Herald Leader
EU reviews cancer drug from Merck and Endocyte
Filed under: drug rehab treatment ny
NEW YORK (AP) — Merck & Co. and Endocyte Inc. said Tuesday that European Union regulators will review their drug vintafolide as a treatment for ovarian cancer. The companies said the European Medicines Agency will review vintafolide as a treatment for …
Read more on Businessweek